

As the Lights Dim for Earth Hour, the ClikSTAR® Shines Bright Eco-friendly pen now available for use with Lantus® and Apidra® insulins

Laval, Quebec – March 24, 2010 – Canadians with diabetes who require both long-acting and rapid-acting insulin at mealtimes are now able to make a significant difference for the planet without changing their routine. The award winning, ClikSTAR reusable insulin pen is now available for use with Lantus and Apidra in Canada. If 25 people were to use the ClikSTAR reusable pen, landfills would be spared nearly 1,000 pens each year. Lining them up, that's more than three times the length of an Olympic-size pool.

“Patients will appreciate the fact that we now offer a new device that is easy to use and easy to refill,” says Kathy Megyery, Vice-President, Communications, Stakeholder Relations and Public Policy. “It's not always easy to balance the needs of patients with those of the environment. By using this eco-friendly insulin delivery device, patients can play a significant role in protecting the environment, given that one ClikSTAR can be used for as long as four years.”

The result of more than four years of intensive development, ClikSTAR was designed with the help of nearly 2,000 patients and 500 healthcare professionals to ensure that the device met the needs, and high standards, of its users and prescribers.

ClikSTAR has been so well received by both patients and healthcare providers alike that The Chicago Athenaeum: Museum of Architecture and Design presented it with a 2009 GOOD DESIGN™ award — one of the world's most prestigious global awards for new product design and graphics.

About Lantus and Apidra

Lantus is a recombinant human insulin analog approved for once-daily administration in the treatment of patients over the age of 17 with type 1 or type 2 diabetes who require basal (long-acting) insulin for the control of hyperglycemia (abnormally high blood sugar). Lantus is also indicated in the treatment of pediatric patients with type 1 diabetes.

Apidra is a rapid-acting recombinant human insulin analog that offers patients (both type 1 and type 2) mealtime dosing flexibility. The injection can be administered up to 15 minutes before or within 20 minutes after starting a meal.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi-aventis is represented in Canada by the pharmaceutical company sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines company Sanofi Pasteur Limited, based in Toronto, Ontario. Together they employ more than 2,000 people and are leaders in Canada's biopharmaceutical sector, a critical research-based industry that generates jobs, business and opportunity throughout the country.

-30-

For more information, or to arrange interviews, please contact:

Rebecca Crittenden, Debra Quinn or Catherine Héroux at Strategic Objectives

Tel: 1-866-366-7733

Email: rcrittenden@strategicobjectives.com

Claudette Baltayan at Sanofi-aventis Canada

Tel: 514-856-8748

Email: Claudette.Baltayan@sanofi-aventis.com